论文部分内容阅读
抗心律失常药物的心电生理—电药理学试验(EPT)是将心脏电生理与临床药理学结合起来的一门新型边缘学科。近二十年来,EPT越来越多地应用于反复发作性室性心动过速(VT)和心室颤动(VF)的防治研究。本文就近年来冠心病猝死(CA)防治的EPT研究近况作一概述。一、指导临床用药 EPT对CA病人的防治有很好的指导价值,但也有不同意见。约70～80％的院外CA幸存者可用程控刺激(PES)诱发VT/VF,其中36～51％的患者可诱发持续性单形VT(SVT),其余病人可诱发非持续性VT(NSVT)或由多形性VT转变的VF。未诱发VT/VF的病人预后明显好于可诱发VT/VF的患者。对照状态下可诱发VT的病人
Cardiac electrophysiology of anti-arrhythmic drugs - Electro-pharmacological tests (EPTs) are a new type of fringe discipline that combines cardiac electrophysiology with clinical pharmacology. In the recent two decades, EPT is increasingly used in the prevention and treatment of recurrent ventricular tachycardia (VT) and ventricular fibrillation (VF). This article in recent years, sudden death of coronary heart disease (CA) prevention and treatment of EPT research made an overview. First, the guidance of clinical medication EPT has a good guiding value for the prevention and treatment of CA patients, but there are also different opinions. Approximately 70-80% of hospital-based CA survivors can induce VT / VF with program-controlled stimulation (PES), of whom 36-51% can induce persistent monomorphic VT (SVT) and the remaining patients can induce non-persistent VT (NSVT) Or VF transformed by polymorphic VT. Patients without VT / VF have significantly better outcomes than those with VT / VF. Controlled patients can induce VT